Skip to content
Credit reportVerdict and grounds
Made on 20-11-2026 at 15:14
Reference CK-0803488513-20261120

BUMA PHARMA

ActivePrivate limited company0803.488.513Oudestraat 121, 2610 Antwerp
Retail sale of pharmaceutical products (NACE 47730) · founded in 2023 · one director · accounts in the micro format

Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 05-08-2026; the Belgian Official Gazette, latest deed of 05-07-2023.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,304 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€22,296
▼ 3.0% against 2024
Net result
€14,746
▼ 4.0% against 2024
Equity
€38,507
▲ 56.6% against 2024
Cash
€55,063
▲ 45.7% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. BUMA PHARMA made a profit in every financial year since 2023.Annual accounts 2023 to 2025 page 2
  2. Equity stands at €38,507, or 67.3% of the balance sheet total of €57,247. The solvency of 67.3% is higher than at 78% of the 25,414 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
  3. BUMA PHARMA paid out €833 in dividends, 6% of the profit of 2025.Annual accounts 2025 page 2
  4. The 2025 accounts reached the National Bank on 05-08-2026, 5 days after the term.National Bank, filing of 05-08-2026 page 4

Representation

The signing rule is in the deed of 05-07-2023.

Articles of association, Belgian Official Gazette of 05-07-2023, deed 23366510

Ownership

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 05-07-2023

BUMA PHARMA · 0803.488.513 · credit report of 20-11-2026Page 1 of 5
BUMA PHARMA0803.488.513 · report of 20-11-2026

Financial situation

Annual accounts 2023 to 2025, as filed with the National Bank

Gross margin and net resultin euro

202314,894202422,990202522,29620239,918202415,368202514,746
gross marginnet result

Equity and debtsin euro

20232024202538,50718,740
equitydebts

Cashin euro

202320,400202437,802202555,063
on the balance sheet date
Financial year20235 months20242025Trend
Results
Gross margin€14,894€22,990€22,296
Operating result€13,684€21,677€20,857
Net result€9,918€15,368€14,746
Balance sheet at the closing date
Equity€10,085€24,593€38,507
Debts€14,325€16,754€18,740
Debts due within one year€14,314€16,754€18,740
Cash€20,400€37,802€55,063
Balance sheet total€24,410€41,347€57,247
Ratios
Solvency41.3%59.5%67.3%
Liquidity1.432.262.94

Source: Annual accounts 2025, micro format, filed on 05-08-2026 (2026-00390280); Annual accounts 2024, micro format, filed on 30-08-2025 (2025-00476101); Annual accounts 2023, filed on 30-08-2024 (2024-00453593).

Debts rose by €1,986 in 2025, of which €161 to suppliers. A dividend stands among the debts on the balance sheet date until it is paid.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

BUMA PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €22,990 to €22,296.

The financial year to 31-12-2023 ran for 5 months.

BUMA PHARMA · 0803.488.513 · credit report of 20-11-2026Page 2 of 5
BUMA PHARMA0803.488.513 · report of 20-11-2026

Board, signature and ownership

Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 05-07-2023.

Articles of association, Belgian Official Gazette of 05-07-2023, deed 23366510

Board

one director in office
Director (not named in the articles)appointed by deed of 05-07-2023
term without a fixed enddeed of 05-07-2023

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 05-07-2023

BUMA PHARMA · 0803.488.513 · credit report of 20-11-2026Page 3 of 5
BUMA PHARMA0803.488.513 · report of 20-11-2026

Events and comparison

Every event since the founding, newest first

Annual accounts 2025 filed, 5 days late.

NBB filing

Annual accounts 2024 filed, 30 days late.

NBB filing

Highest result from 2023 to 2025. The operating result of €21,677 and the net result of €15,368 are both a record.

Financial

Annual accounts 2023 filed, 30 days late.

NBB filing

Incorporation. Founding capital of €1,000, 100 shares. Founded by . appointed as director. Published on 05-07-2023.

Gazette, deed 23366510

First establishment. Oudestraat 121, Antwerp.

Comparable companies, two years later

In July 2024, 39,332 companies had the same profile as BUMA PHARMA has now: micro, 2 to 5 years old, solvency 30% or more and a profit of 5% of the balance sheet or more. Two years later 95.7% were still trading, 2.5% had stopped another way and 1.8% had gone bankrupt.

still trading 95.7% stopped another way 2.5% bankrupt 1.8%

The return on assets of BUMA PHARMA, 25.8%, is higher than at 89% of the 24,603 companies filing micro accounts in retail trade (NACE 47) in 2025.

Other findings

Peppol

Reachable for e-invoices since 07-12-2025, under 0208:0803488513.

Sanctions lists

BUMA PHARMA · 0803.488.513 · credit report of 20-11-2026Page 4 of 5
BUMA PHARMA0803.488.513 · report of 20-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units20-11-2026KBO 0803.488.513
National Bank of BelgiumAnnual accounts 2025, micro format05-08-20262026-00390280
National Bank of BelgiumAnnual accounts 2024, micro format30-08-20252025-00476101
National Bank of BelgiumAnnual accounts 2023 to 202330-08-20242024-00453593
Belgian Official GazetteArticles of association with the signing rule05-07-2023deed 23366510
Peppol DirectoryRegistration for e-invoices07-12-20250208:0803488513
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies19-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

BUMA PHARMA · 0803.488.513 · credit report of 20-11-2026Page 5 of 5